Related by context. All words. (Click for frequent words.) 79 safety tolerability 77 safety tolerability pharmacokinetic 77 pharmacodynamics 75 pharmacokinetics PK 73 tolerability pharmacokinetics 73 pharmacodynamic profile 73 pharmacokinetics 72 ascending doses 71 ascending dose 69 dose escalation trial 69 pharmacokinetic parameters 69 label dose escalation 68 pharmacokinetic profile 68 pharmacodynamic effects 68 tolerability 68 pharmacodynamics PD 68 tolerated dose MTD 68 safety tolerability pharmacodynamics 68 blinded randomized placebo controlled 67 dose escalation study 67 pharmacokinetics pharmacodynamics 66 single ascending dose 66 multicenter Phase II 66 nab paclitaxel 66 active comparator 65 dose dose escalation 65 pharmacodynamic 65 maximally tolerated dose 65 Phase 1b trial 65 placebo controlled dose escalation 65 blind placebo controlled 65 subcutaneous SC 64 blind randomized placebo 64 Phase 2a trial 64 Phase 2b study 64 controlled multicenter 64 Omacetaxine mepesuccinate 64 Phase Ib clinical 64 efficacy tolerability 64 Phase 1b clinical 64 pharmacodynamic PD 64 subcutaneous formulation 64 pharmacokinetic 64 multiple ascending dose 63 blinded placebo controlled 63 dose cohorts 63 placebo controlled 63 double blinded placebo 63 analgesic efficacy 63 ritonavir boosted 63 Phase Ib 63 dose escalation clinical 63 investigational oral 63 Phase 1b 63 dosing regimens 63 dose regimens 63 urate lowering 63 Phase Ib II 63 multicenter Phase III 62 randomized multicenter 62 randomized placebo controlled 62 placebo controlled randomized 62 pharmacodynamic properties 62 double blind placebo 62 pharmacodynamic markers 62 #mg QD [002] 62 pharmacodynamic profiles 62 subcutaneously administered 62 dose escalation Phase 62 multicenter randomized double 62 SCH # 62 TMC# C# 62 label multicenter 62 multicenter randomized 62 phase IIb clinical 62 ZYBRESTAT fosbretabulin 62 RG# ITMN 62 oral prodrug 62 oral deforolimus 62 dose cohort 62 treatment naive genotype 62 mg TID 62 phase Ib 61 pharmacokinetic profiles 61 Phase IIa trial 61 placebo controlled Phase 61 masked placebo controlled 61 pharmacokinetic PK 61 Phase Ib clinical trials 61 selective modulator 61 galiximab 61 PRTX 61 oral rivaroxaban 61 primary hypercholesterolemia 61 investigational protease inhibitor 61 pharmacokinetic PK profile 61 randomized double 61 polymerase inhibitor 61 alvespimycin 61 multicenter randomized placebo controlled 61 evaluating tivozanib 61 HGS ETR2 61 Elvitegravir 61 subcutaneous doses 61 double blinded randomized 61 PSN# [002] 60 intermittent dosing 60 ACTEMRA TM 60 novel VDA molecule 60 phase IIa clinical 60 teriflunomide 60 desvenlafaxine succinate 60 plus Copegus R 60 Phase Ib study 60 Phase Ia 60 pharmacokinetic pharmacodynamic 60 Phase 2a clinical 60 Phase 1a 60 liposomal formulation 60 CANCIDAS 60 orally administered inhibitor 60 HGS# 60 mg BID 60 administered subcutaneously 60 IMC A# 60 ascending dose study 60 dose limiting toxicities 60 Phase 2b randomized 60 investigational humanized monoclonal antibody 60 multicentre randomized 60 pertuzumab 60 CTA# Injection 60 treatment naïve genotype 60 antiviral efficacy 60 Phase IIa clinical 60 Maximum Tolerated Dose MTD 60 Imprime PGG 60 optimal dosing 60 AAG geldanamycin analog 60 nucleotide analog 60 PEG Interferon lambda 60 thorough QT 60 JAK inhibitor 60 KRN# 60 aflibercept VEGF Trap 60 randomized Phase III 60 GAMMAGARD 60 Pegasys ® 60 huN# DM1 60 efficacy 60 Oral NKTR 60 immunogenicity 60 MEND CABG II 60 randomized #:# 60 Pharmacokinetics PK 60 Poly ICLC 60 INSPIRE Trial Phase III 60 randomized multicenter trial 60 immunomodulator 60 blind randomized 60 HCD# [002] 59 mg QD 59 placebo controlled Phase III 59 limiting toxicity DLT 59 μg dose 59 beta2 agonist 59 peripheral blood mononuclear 59 endothelin antagonists 59 Blinatumomab 59 placebo controlled clinical 59 mcg kg 59 virus HCV protease inhibitor 59 lorvotuzumab mertansine 59 CYT# 59 CIMZIA TM certolizumab pegol 59 relapsed MM 59 dasatinib Sprycel ® 59 fosbretabulin 59 viral kinetics 59 NP2 Enkephalin 59 cannabinor 59 dosage regimens 59 REVIVE Diabetes 59 rALLy clinical trial 59 LEXIVA r 59 AEGR 59 Phase IIa 59 CK # administered 59 8mg/kg 59 CR# vcMMAE 59 peripherally acting 59 hypoxia activated prodrug 59 erlotinib Tarceva ® 59 dosing cohorts 59 humanized anti 59 DermaVir Patch 59 intravenous bolus 59 pomalidomide 59 Phase #/#a 59 unique alkylating agent 59 AKT inhibitor 59 pharmacokinetic studies 59 davunetide intranasal AL 59 mapatumumab 59 cilengitide 59 PXD# 59 velafermin 59 riociguat 59 dose escalation 59 plus prednisone 59 blind placebo 59 R#/MEM # 59 Phase III randomized 59 #I TM# 59 CML CP 59 refractory NSCLC 59 ORMD 59 randomized controlled 59 Teriflunomide 59 Phase 1a clinical 59 CIMZIA TM 59 #mg/m# [002] 59 Panzem R NCD 59 visilizumab 59 Traficet EN 58 multinational multicenter randomized 58 oral antiviral 58 subcutaneous PRO 58 varespladib 58 orally dosed 58 randomized blinded 58 nucleoside analog 58 Phase #b/#a trial 58 #mg/m# [001] 58 MIRCERA 58 lintuzumab SGN 58 RSD# oral 58 Androxal TM 58 orally bioavailable 58 prospective randomized multicenter 58 docetaxel chemotherapy 58 intravenously administered 58 neratinib 58 preclinically 58 HGS ETR1 mapatumumab 58 plus prednisone prednisolone 58 RG# [001] 58 imetelstat 58 HCV RESPOND 2 58 IAP inhibitor 58 receptor inhibitor 58 metastatic HRPC 58 MAGE A3 ASCI 58 telaprevir dosed 58 Omacetaxine 58 relapsed refractory multiple myeloma 58 CG# [003] 58 randomized controlled Phase 58 celgosivir 58 urocortin 2 58 investigational hepatitis C 58 elotuzumab 58 thymalfasin 58 Phase IIIb clinical 58 anti leukemic 58 HCV NS5B polymerase 58 pegylated interferon alfa 2a 58 diabetic neuropathic pain 58 MGd 58 EGFR HER2 58 PEG PAL 58 recurrent malignant gliomas 58 pharmacokinetic properties 58 GRN#L 58 orally inhaled migraine 58 Phase IIb clinical 58 Initiate Phase 58 forodesine 58 plus ribavirin 58 daunorubicin 58 label multicenter Phase 58 PKC# 58 phase IIb 58 prospective randomized controlled 58 Sapacitabine 58 CIMZIA ™ 58 Chemophase 58 antibody MAb 58 Cloretazine 58 controlled dose escalation 58 placebo controlled multicenter 58 prasterone 58 dosing schedules 58 4mg/kg 58 serotonin norepinephrine reuptake inhibitor 58 Kahalalide F 58 PRT# 58 rHuPH# 58 abacavir lamivudine 58 Initiated Phase 58 IIa clinical 58 2 methoxyestradiol 58 pharmacokinetic PK study 58 phase Ib clinical 57 alfa 2a 57 PEG SN# 57 QD dosing 57 docetaxel Taxotere R 57 NOX E# 57 CLORETAZINE TM VNP#M 57 rhIGF-I/rhIGFBP-3 57 null responder HCV 57 PEGylated interferon beta 1a 57 RE SURGE 57 HCV SPRINT 57 CDK inhibitor 57 PREZISTA r 57 Preclinical studies suggest 57 Cloretazine R VNP#M 57 phase IIa 57 Tarceva TM 57 prospective observational 57 mcg dose 57 BAY #-# 57 Fx #A 57 vapreotide acetate 57 Pegasys R 57 weekly subcutaneous injections 57 antiviral activity 57 aplindore 57 prospectively defined 57 protease inhibitor PI 57 dosing cohort 57 prospective multicenter randomized 57 dyskinesia PD LID 57 IMiDs ® 57 antitumor activity 57 Phase IIb III 57 Azedra 57 investigational drug 57 trastuzumab Herceptin R 57 cetuximab Erbitux R 57 metaglidasen 57 viral kinetic 57 adecatumumab 57 Phase III placebo controlled 57 OMP #M# 57 SAR# [004] 57 recurrent malignant glioma 57 multicentre randomized double 57 Posiphen 57 Phase 2b clinical 57 PDE4 inhibitor 57 multicenter Phase 57 FOLOTYN ® 57 naïve HCV 57 Phase 2b trial 57 FOLFOX6 chemotherapy regimen 57 Carfilzomib 57 ongoing Phase 1b 57 achieved statistical significance 57 class mGluR5 inhibitor 57 mg qd 57 low dose cytarabine 57 Primary endpoints 57 #beta estradiol 57 venlafaxine XR 57 INCB# [001] 57 APTIVUS r 57 histone deacetylase inhibitor 57 phase 2a 57 mg RDEA# 57 dose regimen 57 #mg dose [001] 57 plus dexamethasone 57 5 FU leucovorin 57 non nucleoside inhibitor 57 prokinetic agent 57 Phase III multicenter 57 q8h 57 intravesical 57 sunitinib malate 57 synthetic retinoid 57 CD4 monoclonal antibody 57 EZN 57 dose pharmacokinetic 57 relapsed multiple myeloma 57 ALN HPN 57 By JENNIFER LEARN 57 Phase IIb trial 57 NS5B polymerase 57 interferon gamma 1b 57 mg/m2 dose 57 dosed orally 57 long acting muscarinic 57 budesonide MMX 57 HGS ETR1 57 CCR5 mAb 57 melphalan prednisone 57 vivo toxicology 57 registrational 57 immune modulator 57 intravenous dose 57 dexamethasone Decadron 57 ENMD # 57 sunitinib Sutent ® 57 Pralatrexate 57 hour bronchodilation 57 PSMA ADC 57 RE LY ® 57 tanespimycin 57 PDX pralatrexate 57 randomized clinical 57 PI3K/Akt pathway inhibitor 57 castrate resistant prostate cancer 57 subcutaneous dose 57 LUX Lung 57 dose escalation phase 57 sorafenib Nexavar ® 57 crizotinib PF # 57 mg dose 57 HMG CoA reductase inhibitor 57 vicriviroc 57 beclomethasone dipropionate 57 Luteinizing Hormone Releasing Hormone 57 Phase IIIb 57 blinded randomized 57 pegylated alpha interferon 57 GLPG# 57 Val MARC 57 #mg BID [003] 57 CorVue ™ 57 Afatinib 57 NOXAFIL Oral Suspension 57 randomized 57 investigational compound 57 antitumor effect 56 fluticasone furoate 56 darunavir ritonavir 56 bendamustine 56 phase IIb trial 56 IMiDs R 56 trastuzumab emtansine T DM1 56 PF # [001] 56 refractory CLL 56 plasma pharmacokinetics 56 afatinib 56 Tolvaptan 56 phase IIb study 56 Elotuzumab 56 randomized crossover 56 Phase #/#a clinical 56 mg kg dose 56 non inferiority 56 ganetespib 56 multicenter multinational 56 teduglutide 56 Forodesine HCl 56 sulodexide 56 Enzastaurin 56 acting muscarinic antagonist 56 TO AVOID PREGNANCY WHILE 56 pregabalin Lyrica 56 GMX# 56 Dual Opioid 56 bevacizumab Avastin R 56 Kinoid 56 etoposide 56 observer blinded randomized 56 GLYX 56 docetaxel 56 generation purine nucleoside 56 controlled multicenter Phase 56 placebo controlled studies 56 pharmacokinetic characteristics 56 mCi kg 56 dirucotide MBP# 56 pharmacodynamic parameters 56 receptor tyrosine kinase inhibitor 56 systemically administered 56 rNAPc2 56 prucalopride 56 velafermin belinostat 56 telaprevir VX 56 hA# 56 relapsed CLL 56 irbesartan 56 GetGoal Phase III 56 CYP#A# CYP#D# 56 efavirenz EFV 56 metreleptin 56 erythropoietic 56 systemic RNAi therapeutic 56 relapsing multiple sclerosis 56 huC# DM4 56 phase III ACCLAIM 56 GATTEX ® 56 peginterferon alfa 2a 56 ZOLINZA 56 oral mTOR inhibitor 56 retaspimycin 56 multicenter randomized controlled 56 peginterferon alfa 2b 56 edoxaban 56 Phase #b/#a 56 dacetuzumab 56 vorinostat 56 sodium glucose cotransporter 56 RDEA# 56 favorable pharmacokinetic profile 56 gemcitabine 56 preclinical efficacy 56 certolizumab 56 saline placebo 56 somatostatin analog 56 pathophysiological effects 56 recurrent glioblastoma multiforme 56 multicentre 56 novel histone deacetylase 56 MTP inhibitor 56 mg/m2 56 elvitegravir 56 insulin degludec 56 urinary N telopeptide 56 mertansine 56 daily Infergen 56 secondary efficacy endpoints 56 nitazoxanide 56 sorafenib tablets 56 monotherapy 56 blind multicenter 56 topically administered 56 ribavirin RBV 56 Engerix B 56 CD# monoclonal antibody 56 eniluracil 56 comparator arm 56 mixed dyslipidemia 56 Phase IIb randomized 56 MEND CABG 56 piperacillin tazobactam 56 budesonide foam 56 Methylnaltrexone 56 ritonavir boosted atazanavir 56 APTIVUS 56 fallopian tube cancers 56 selective antagonist 56 randomized controlled multicenter 56 interferon alfa 2b 56 golimumab CNTO 56 Sym# 56 XL# XL# XL# XL# 56 label dose titration 56 albinterferon alfa 2b 56 Phase IIb 56 mg/m2/day 56 AEG# 56 IIIa inhibitor 56 Phase IIb clinical trials 56 angiotensin receptor blocker ARB 56 D aspartate NMDA receptor 56 pegylated interferon alpha 56 maximal tolerated 56 evaluating Actimmune 56 randomized Phase 2b 56 Liposomal 56 CEQ# 56 Phase 2a 56 dexpramipexole 56 prospective randomized placebo 56 ceftazidime 56 Laquinimod 56 Trandolapril 56 pyrimidine nucleoside analog 56 docetaxel Taxotere ® 56 pharmacodynamic endpoints 56 solithromycin 56 EmbraceAC 56 JVRS 56 DLTs 55 intravitreal insert 55 imatinib resistant 55 APOPTONE 55 continuous intravenous infusion 55 omega interferon 55 pramlintide 55 confirmatory clinical 55 TNFalpha 55 antitumor effects 55 opioid naive 55 PEGylated anti 55 romidepsin 55 potent CYP#A# inhibitors 55 chemotherapy FOLFOX 55 APPRAISE 55 antisense drug 55 biodistribution 55 sorafenib Nexavar 55 placebo controlled clinical trials 55 Pharmacokinetic 55 torezolid phosphate 55 pharmacokinetic equivalence 55 anti amnesic 55 small molecule chemotherapeutic 55 vidofludimus 55 ALN TTR 55 R baclofen 55 Hsp# Inhibitor 55 doxorubicin cyclophosphamide 55 stated Michelle Berrey 55 inhibitor RG# 55 EMPHASIS HF trial 55 BRIM2 55 GFT# 55 6R BH4 55 IMGN# 55 dacarbazine 55 AIR CF1 55 eculizumab 55 oral Azacitidine 55 painful diabetic neuropathy 55 ALN TTR# 55 cariprazine 55 Spiegelmer ® 55 orally administered 55 prospectively randomized 55 lispro 55 novel chimeric natriuretic 55 vitro cytotoxicity 55 Pharmacokinetic parameters 55 ABSORB clinical 55 clomipramine 55 oral Janus kinase 55 axitinib 55 Multimeric 55 teplizumab 55 refractory cutaneous T 55 glatiramer acetate 55 trial evaluating PRX# 55 coadministration 55 IV bolus 55 intravenous dosing 55 NEUGENE antisense 55 Alzhemed TM 55 immunomodulatory therapy 55 nucleoside naive 55 PEG IFN 55 NGX# 55 octreotide acetate 55 relapsing remitting multiple sclerosis 55 telaprevir dosing 55 CYC# 55 intravesical instillation 55 nonrandomized 55 COU AA 55 lesinurad 55 tolerability profile 55 TBC# 55 Triolex 55 LEVADEX 55 GSK# [001] 55 mitoxantrone 55 prospective multicenter 55 GW# [003] 55 bicifadine 55 pharmacologically active isomer 55 BENLYSTA ® 55 highly selective inhibitor 55 Pimavanserin 55 highly selective endothelin 55 Natalizumab 55 ELACYT 55 IMiDs 55 azilsartan medoxomil 55 mg simvastatin 55 evaluating REVLIMID 55 Triapine R 55 randomized Phase 55 YONDELIS 55 Apoptone 55 REVLIMID lenalidomide 55 MEK inhibitor 55 heavily pretreated 55 PNP inhibitor 55 non splenectomized 55 motesanib 55 label multicenter randomized 55 RELOVAIR ™ 55 PEGPH# 55 Phase IIB 55 noninferiority 55 randomized controlled clinical 55 hENT1 55 estramustine 55 administered orally 55 zonisamide SR 55 refractory chronic lymphocytic 55 chlorambucil 55 selectively inhibits 55 TACI Ig 55 antiretroviral naive 55 inhalations twice 55 ADP receptor antagonist 55 tirofiban 55 pivotal Phase 55 Phase IIIb study 55 cathepsin K inhibitor 55 Empatic 55 bevacizumab Avastin ® 55 pan HDAC inhibitor 55 randomized #:#:# 55 avosentan 55 Navelbine 55 GRNVAC1 55 PegIFN 55 Proellex TM 55 CYT# potent vascular disrupting 55 relapsed MCL 55 Neulasta R 55 prospective randomized 55 hyperphenylalaninemia HPA due 55 TPI ASM8 55 q#h 55 monoclonal antibody IgG1 Mab 55 pramlintide metreleptin combination 55 ARIKACE 55 Folfox 55 lamivudine zidovudine 55 demonstrated antitumor activity 55 peginterferon alfa 2a #KD 55 trabedersen 55 EOquin TM phase 55 otelixizumab 55 5 HT2A inverse 55 AVE# 55 adecatumumab MT# 55 depsipeptide 55 ROCKET AF 55 Tyrima 55 vinca alkaloid 55 tasimelteon 55 MAP# 55 Seliciclib 55 dose cytarabine 55 bevirimat Study 55 gemcitabine cisplatin 55 Oral Fingolimod 55 reactogenicity 55 dabigatran etexilate 55 partial agonist 55 idarubicin 55 mg/m2 administered 55 oral JAK#/JAK# inhibitor 55 CYP#C# genotype 55 icatibant 55 Secondary endpoints include 55 Phase III clinical 55 II Clinical Trial 55 Alocrest 55 LAB CGRP 55 uric acid lowering 55 Solid Tumors 55 Ataluren 55 baminercept 55 Amrubicin 55 adjuvant GIST 55 VEGFR2 inhibitor 55 dose proportionality 55 cyclophilin inhibitor 55 CLARITY study 55 5 HT2C receptor 55 Aflibercept 55 CCX# B 55 posaconazole 55 rapid virologic response 55 relapsed myeloma 55 FEMALES SHOULD BE ADVISED 55 ZACTIMA 55 bevirimat 55 peg IFN 55 zileuton 55 atazanavir ritonavir 55 albiglutide 55 ANCHOR trial 55 registrational trial 55 plus COPEGUS 55 ug dose 55 designated HVTN 55 sitaxsentan 55 NO# [002] 55 EXPLORE Xa 54 HER2 positive metastatic breast 54 familial amyloidotic polyneuropathy FAP 54 insulin aspart 54 #mg/day [001] 54 intradermal injections 54 latrepirdine 54 phase IIIb 54 daily subcutaneous injections 54 JAK2 inhibitor 54 lixisenatide 54 TMC# r 54 cell lymphoma CTCL 54 Archexin 54 VELCADE melphalan 54 Aplidin R 54 cytarabine 54 pain palliation 54 superficial bladder cancer 54 boosted protease inhibitor 54 Phase III confirmatory 54 CBLC# 54 ZD# [001] 54 Exelixis compounds 54 Telintra 54 PRIMO CABG 54 DU #b 54 Phase 1b clinical trials 54 randomized multicenter Phase III 54 clinical trials Archexin ® 54 TRO# 54 pharmacokinetic interactions 54 PPAR gamma agonist 54 Clonicel 54 Mg Uk 54 DEB# 54 Linagliptin 54 REMINYL ® 54 HMG CoA reductase inhibitors 54 prednisone prednisolone plus 54 rheumatoid arthritis psoriatic arthritis 54 adalimumab 54 gemcitabine Gemzar ® 54 multicenter phase 54 dextromethorphan quinidine 54 pivotal Phase III 54 G CSF 54 nonclinical studies 54 bosentan 54 humanized therapeutic 54 intravesical infusion therapy 54 pegylated interferon alfa 2b 54 PS# [001] 54 Dapagliflozin 54 ritonavir boosted danoprevir 54 FOLFOX 54 decitabine 54 Interferon alpha 54 XP# Transported Prodrug 54 genotypic resistance 54 ISIS # 54 carboplatin paclitaxel 54 fenofibric acid 54 selective agonist 54 randomized multicentre 54 inhaled corticosteroid ICS 54 NATRECOR R 54 BMS # 54 ON #.Na 54 Bicifadine 54 cobicistat 54 Betaferon ® 54 mGluR5 NAM 54 HCV protease 54 GLP toxicology studies 54 oral ridaforolimus 54 Kinesin Spindle Protein KSP 54 Enhanze Technology 54 trodusquemine 54 Phase IIA 54 tipifarnib 54 generation PNP inhibitor 54 multicenter placebo controlled 54 Phase IIb trials 54 S/GSK# 54 ofatumumab 54 REG2 54 talabostat 54 non nucleoside HCV 54 Zenvia ™ 54 Dacogen injection 54 Tarvacin TM 54 multicenter clinical 54 autoantibody positive 54 Phase 2b clinical trials 54 de novo kidney transplant 54 cyclophosphamide methotrexate 54 glufosfamide 54 GATTEX ™ 54 factor Xa inhibitor 54 pegylated interferon 54 somatostatin analogue 54 #mg QD [001] 54 confirmatory Phase III 54 AP# [003] 54 NATRECOR ® 54 weekly intravenous infusions 54 Golimumab 54 intranasal formulation 54 Ceplene/IL-2 54 receptor antagonist 54 antidiabetic 54 serum phosphorous 54 capecitabine Xeloda R 54 docetaxel Taxotere 54 histone deacetylase HDAC inhibitor 54 reslizumab 54 GAMMAGARD LIQUID 54 investigational pan BCR 54 either acutely decompensated 54 telomerase inhibitor drug 54 AERAS-#/Crucell Ad# 54 C1 INH 54 enzastaurin 54 multicenter 54 doripenem 54 peritumoral brain edema 54 mcg doses 54 plasma concentrations 54 Adalimumab 54 Pegasys plus Copegus 54 insulin glargine rDNA origin 54 factorial design 54 mg kg 54 Panzem NCD 54 metformin sulfonylurea 54 PHX# 54 tipranavir r 54 LEP ETU 54 evaluating Xcytrin 54 TMC# [002] 54 integrin inhibitor 54 fostamatinib 54 topical gel formulation 54 dihydroergotamine DHE 54 Cannabinor 54 FFNS 54 candesartan cilexetil 54 TAXUS V 54 Pharmacokinetic PK 54 subcutaneous dosing 54 clinical trial 54 viral tropism 54 mGluR5 negative 54 CCR5 antagonist 54 ADVANCE PD 54 lomitapide 54 Copegus ® ribavirin 54 buprenorphine naloxone 54 Ocrelizumab 54 sipuleucel T 54 Telik logo TELINTRA 54 apremilast 54 lanreotide 54 perampanel 54 direct thrombin inhibitor 54 irinotecan doxorubicin oxaliplatin paclitaxel 54 dasatinib Sprycel 54 Dabigatran etexilate 54 inhaled iloprost 54 risperidone Risperdal 54 Medidur TM FA 54 REOLYSIN ® 54 Vilazodone 54 Darusentan 54 Annamycin 54 MoxDuo TM IR 54 5 HT2A receptor 54 DAVANAT 54 Prodarsan ® 54 active metabolite 54 immunomodulatory effects 54 ocular formulation 54 Interferon beta 1a 54 preclinical pharmacokinetic 54 Copegus ribavirin 54 administered intranasally 54 Mg Usa 54 tgAAC# 54 ADI PEG 54 liposomal doxorubicin 54 TG# [003] 54 serum cortisol 54 subcutaneous injections 54 #mg q8h 54 CRLX# 54 humanized monoclonal antibody 54 Vidofludimus 54 midstage clinical 54 Iloperidone 54 serum concentrations 54 CRx 54 virus HCV infection 54 carboplatin 54 IMiDs ® compound 54 Randomized Double blind 54 ispinesib administered 54 basal bolus regimen 54 mg kg BID